Internal medicine physicians in the US and Europe are using clinical trials to push drug approval.
The latest example came from an internal medicine physician in Ohio who told the Columbus Dispatch she was not surprised to learn her former boss had taken part in a clinical study that she believed showed a drug would help reduce chronic pain in people with chronic conditions like Crohn’s disease.
“I can tell you that if you follow the directions and go through the process of being able to give the drug, you will be better off,” Dr. Kimberly Gebhart told the Dispatch.
Gebhart is a professor of internal medicine at Ohio State University’s Cleveland Clinic and an active member of the American Society of Internal Medicine (ASIM), an association of more than 150 medical schools and clinics.
She was previously the head of internal affairs at a private hospital in Columbus, Ohio.
She did not respond to multiple requests for comment about the trial and the role she took part in it.
Goblin and his co-author, Dr. Michael Osterholm, told the paper they were “extremely disappointed” that the trial did not provide evidence that their drug worked in clinical trials.
But they say it’s important for doctors to know about clinical trials before they sign up to treat patients.
“We were hoping that the results would show something that could help people in the clinic, so that they could go on to get the drug.
It wasn’t that,” Goblin said in an interview with the Dispatch published on Thursday.
Goblins co-authors are working to publish the results of the trial, but he said they expect to be able to get some of the data before it’s published.
They are hoping to get a clinical report on the trial soon.
The trial was funded by the National Institutes of Health, the Department of Veterans Affairs, and the Centers for Medicare & Medicaid Services.